{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05867121",
            "orgStudyIdInfo": {
                "id": "GO44010"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-502615-11-00",
                    "type": "OTHER",
                    "domain": "EU Clinical Trial Number"
                }
            ],
            "organization": {
                "fullName": "Genentech, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors",
            "officialTitle": "A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-in-combination-with-a-checkpoint-inhibitor-with-or-without-standard-of-care-chemotherapy-in-participants-with-locally-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-10",
            "studyFirstSubmitQcDate": "2023-05-10",
            "studyFirstPostDateStruct": {
                "date": "2023-05-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Genentech, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Chugai Pharmaceutical Co.",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Solid Tumor",
                "Non-small Cell Lung Cancer",
                "Gastric Cancer",
                "Pancreatic Ductal Adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 120,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort A: NSCLC",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with NSCLC will receive RO7496353, and atezolizumab, given as an intravenous (IV) infusion at an assigned dose on Day 1 of each 21-day cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.",
                    "interventionNames": [
                        "Drug: RO7496353",
                        "Drug: Atezolizumab"
                    ]
                },
                {
                    "label": "Cohort B: GC",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with GC will receive RO7496353, nivolumab, and oxaliplatin, given as an IV infusion at an assigned dose on Day 1 of each 21-day cycle along with either capecitabine or S-1, orally, twice daily on Days 1 to 14 of each cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.",
                    "interventionNames": [
                        "Drug: RO7496353",
                        "Drug: Capecitabine",
                        "Drug: S-1",
                        "Drug: Nivolumab",
                        "Drug: Oxaliplatin"
                    ]
                },
                {
                    "label": "Cohort C: PDAC",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with PDAC will receive RO7496353, and atezolizumab, given as an IV infusion at an assigned dose on Days 1 and 15 of each 28-day cycle along with nab-paclitaxel, and gemcitabine, also given as an IV infusion on Days 1, 8, 15 of each 28-day cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.",
                    "interventionNames": [
                        "Drug: RO7496353",
                        "Drug: Atezolizumab",
                        "Drug: Nab-paclitaxel",
                        "Drug: Gemcitabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RO7496353",
                    "description": "RO7496353 will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort A: NSCLC",
                        "Cohort B: GC",
                        "Cohort C: PDAC"
                    ],
                    "otherNames": [
                        "SOF 10"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Atezolizumab",
                    "description": "Atezolizumab will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort A: NSCLC",
                        "Cohort C: PDAC"
                    ],
                    "otherNames": [
                        "RO554126 7; Tecentriq"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "Capecitabine will be administered as per the schedules specified in the respective arms",
                    "armGroupLabels": [
                        "Cohort B: GC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "S-1",
                    "description": "S-1 will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort B: GC"
                    ],
                    "otherNames": [
                        "Tegafur/Gimeracil/Oteracil potassium"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Nivolumab will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort B: GC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oxaliplatin",
                    "description": "Oxaliplatin will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort B: GC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nab-paclitaxel",
                    "description": "Nab-paclitaxel will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort C: PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "Gemcitabine will be administered as per the schedules specified in the respective arms.",
                    "armGroupLabels": [
                        "Cohort C: PDAC"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants with Adverse Events (AEs)",
                    "description": "AEs will be reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0).",
                    "timeFrame": "Up to approximately 29 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Plasma Concentration of RO7496353",
                    "timeFrame": "Up to approximately 29 months"
                },
                {
                    "measure": "Percentage of Participants with Anti-Drug Antibody (ADA) to RO7496353",
                    "timeFrame": "Up to approximately 29 months"
                },
                {
                    "measure": "Confirmed Objective Response Rate (ORR) as Determined by the Investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
                    "timeFrame": "Up to approximately 29 months"
                },
                {
                    "measure": "Duration of Response (DOR) as Determined by the Investigator per RECIST v1.1",
                    "timeFrame": "Up to approximately 29 months"
                },
                {
                    "measure": "Progression Free Survival (PFS) as Determined by the Investigator per RECIST v1.1",
                    "timeFrame": "Up to approximately 29 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Cohort A and C: Serum Concentration of Atezolizumab",
                    "timeFrame": "Up to approximately 29 months"
                },
                {
                    "measure": "Cohort A and C: Percentage of Participants with ADA to Atezolizumab",
                    "timeFrame": "Up to approximately 29 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy at least 3 months\n* Adequate hematologic and end organ function\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Measurable disease according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) images within 28 days prior to enrollment\n* Availability of representative tumor specimens in formalin-fixed, paraffin-embedded (FFPE) blocks or at least 15 unstained slides\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 9 months after the final dose of oxaliplatin and within 6 months after the final dose of all other study treatment\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Positive test for human immunodeficiency virus (HIV) infection\n* Positive hepatitis B surface antigen (HbsAg) test, and/or positive total hepatitis B core antibody (HbcAb) test at screening\n* Positive hepatitis C virus (HCV) antibody test at screening\n* Known allergy or hypersensitivity to any component of the RO7496353 formulation or any of the study drugs or their excipients\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: GO44010 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. Only)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA University of California Los Angeles",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Yale School of Medicine",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06510-3206",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Thomas Jefferson University",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "St Vincent'S Hospital",
                    "status": "RECRUITING",
                    "city": "Darlinghurst",
                    "state": "New South Wales",
                    "zip": "2010",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.87939,
                        "lon": 151.21925
                    }
                },
                {
                    "facility": "Flinders Medical Centre",
                    "status": "RECRUITING",
                    "city": "Bedford Park",
                    "state": "South Australia",
                    "zip": "5042",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -35.03333,
                        "lon": 138.56667
                    }
                },
                {
                    "facility": "Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)",
                    "status": "RECRUITING",
                    "city": "Porto Alegre",
                    "state": "RS",
                    "zip": "90610-000",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -30.03306,
                        "lon": -51.23
                    }
                },
                {
                    "facility": "Fondazione Policlinico Universitario A Gemelli",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "state": "Lazio",
                    "zip": "00168",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Azienda Ospedaliera Universitaria Integrata di Verona",
                    "status": "RECRUITING",
                    "city": "Verona",
                    "state": "Veneto",
                    "zip": "37126",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.4299,
                        "lon": 10.98444
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East",
                    "status": "RECRUITING",
                    "city": "Chiba",
                    "zip": "277-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "Kanagawa Cancer Center",
                    "status": "RECRUITING",
                    "city": "Kanagawa",
                    "zip": "241-8515",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 37.58333,
                        "lon": 139.91667
                    }
                },
                {
                    "facility": "Shizuoka Cancer Center",
                    "status": "RECRUITING",
                    "city": "Shizuoka",
                    "zip": "411-8777",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.98333,
                        "lon": 138.38333
                    }
                },
                {
                    "facility": "National Cancer Center Hospital",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "zip": "104-0045",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "The Cancer Institute Hospital of Japanese Foundation For Cancer Research",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "zip": "135-8550",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center - PPDS",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital Yonsei University Health System - Clinical Trials Center Pharmacy",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "120-752",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Auckland City Hospital",
                    "status": "RECRUITING",
                    "city": "Auckland",
                    "zip": "1023",
                    "country": "New Zealand",
                    "geoPoint": {
                        "lat": -36.84853,
                        "lon": 174.76349
                    }
                },
                {
                    "facility": "NEXT Oncology-Hospital Quironsalud Madrid",
                    "status": "RECRUITING",
                    "city": "Pozuelo de Alarcon",
                    "state": "Madrid",
                    "zip": "28223",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.43293,
                        "lon": -3.81338
                    }
                },
                {
                    "facility": "Clinica Universitaria de Navarra",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "state": "Navarra",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Clinica Universidad de Navarra-Madrid",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28027",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Clinico Universitario de Valencia",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                },
                {
                    "id": "D000077150",
                    "term": "Oxaliplatin"
                },
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "C000594389",
                    "term": "Atezolizumab"
                },
                {
                    "id": "D000005641",
                    "term": "Tegafur"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "asFound": "Min",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8760",
                    "name": "Tegafur",
                    "asFound": "Vertical",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M349417",
                    "name": "Atezolizumab",
                    "asFound": "Status",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}